| Name | Title | Contact Details |
|---|
Invio Automation is a prominent provider of custom automation solutions, focusing on designing, building, and integrating advanced systems for high-growth industries. The company serves sectors such as Medical Device & Life Sciences, Renewable Energy, Mobility, Logistics & Fulfillment, and Industrial. With over 65 years of experience, Invio is headquartered in Hudson, NH, and operates seven production sites across North America. The team at Invio consists of hundreds of engineers and skilled professionals dedicated to delivering large-scale automation projects. Their offerings include robotic automation services, development of Autonomous Mobile Robots (AMRs), and a range of specialized solutions such as thermal bonding and precision dispensing. Invio also provides consulting and R&D services to help clients prepare for future automation needs. The company collaborates with a diverse customer base, supporting operations of all sizes across various industries.
Model No. was founded to rethink and elevate our experience in the spaces we design and inhabit. We design and make furnishings that harmonize with the space, lift the human experience, and eliminate our impact on the environment. Our collaborators - architects and design professionals - see the problem: Building and the turnover of commercial interiors generate well-over a third of the worlds CO2 emissions and an endless stream of waste. With these mission-driven partners, we create spaces we want without the waste. Circular at our core, Model No. achieves this through elevated design, regenerative and biodegradable materials, and 3D manufacturing. Starting a project with us begins with an email: info@model-no.com
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
MISSION STATEMENT The mission of San Diego Opera is to deliver exceptional vocal performances and exciting, accessible programs to diverse audiences, focusing on community engagement and the transformative power of live performance. VISION STATEMENT The San Diego Opera will be recognized internationally as a leading example of adaptability, innovation and sustainability in the operatic arts, promoting diversified programming and unique performance venues with world-class and emerging talent. CORE VALUES STATEMENT - Through excellence in innovative programming and education, San Diego Opera provides a lasting cultural service to the community. - Our tradition of excellence in fully staged opera is augmented with new models of opera and venues. Our unique and deep commitment to the community propels us to explore ways of increasing affordability and accessibility. - Through fiscal responsibility and nimble adaptation to the changing marketplace, we protect the future of San Diego Opera. - Our educational and community involvement coupled with relevant programming will build the audience of the future.